Infectious Respiratory Disease Diagnostics Market Size, Share & Trends Analysis By Product (Instruments, Services, Consumables), By Sample (Blood, NPS), By Application, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030

Infectious Respiratory Disease Diagnostics Market Size, Share & Trends Analysis By Product (Instruments, Services, Consumables), By Sample (Blood, NPS), By Application, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030

Infectious Respiratory Disease Diagnostics Market Growth & Trends

The global infectious respiratory disease diagnostics market size is anticipated to reach USD 73.56 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.3% from 2025 to 2030. The decline in market size is majorly attributed to the decline in COVID-19 testing. However, the market without the impact of COVID-19 is expected to grow over the forecast years. The growth can be attributed to an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & nonprofit organizations to introduce novel & innovative products to address the increasing demand. For instance, the global investment in tuberculosis R&D reached USD 915 million, and around USD 401 million was spent by the U.S. government on TB research in 2020.

During the forecast period, the global industry is expected to be driven by the rising incidence of infectious respiratory disorders, such as tuberculosis, RSV, and influenza. According to the UN, pneumonia affects around 4.2 million people every year. Key players are developing innovative techniques to improve production for meeting the growing demand in diagnostics and consumables for the diagnosis of infectious diseases. For instance, OPT Industries Inc. has introduced InstaSwab by utilizing the 3D printing system to address supply shortages of sample collection kits due to the COVID-19 pandemic. These swabs are made of woven lattices to absorb and release more fluid than conventional swabs. Companies are advancing their diagnosis products by using new techniques to gain target-specific and accurate results.

Canon Inc. announced the development of a built-in AEC assistance for digital X-rays in March 2021. The X-ray image sensor enables users to perform picture production and real-time detection of images corresponding to emitted X-rays. Furthermore, in May 2021, the University of California developed an ultrasensitive molecular test to identify the presence of SARS-CoV-2 and influenza A antigens using chip technology. In addition, companies are also launching multiplex tests for the simultaneous diagnosis of RSV, influenza, and COVID-19 respiratory diseases. RT-PCR tests are considered the gold standard for the diagnosis of COVID-19 in patients. However, high prices associated with molecular tests are one of the major factors impeding this market.

The lack of comparable products is another reason for hiked prices. This problem is further compounded by the significant variations in prices for different applications of each molecular diagnostic product. Companies are adopting strategies, such as new product launches and partnerships, to increase the penetration of infectious respiratory disease diagnostics products. For instance, in August 2021, Thermo Fisher Scientific Inc. received EUA for the introduction of two COVID-19 diagnostic products, TaqPath COVID-19 RNase P Combo Kit and TaqPath COVID-19 Fast PCR Combo Kit, in the U.S. market.

Infectious Respiratory Disease Diagnostics Market Report Highlights

• The consumables segment dominated the market and accounted for the largest revenue share of 64.3% in 2024. Technological advancements in diagnostic devices have resulted in more sophisticated testing methods, necessitating specialized consumables.
• The COVID-19 segment dominated the global market in 2024, accounting for 43.8% of the revenue. Increased COVID-19 variants, product approvals, and heightened research and development efforts drove this dominance.
• North America infectious respiratory disease diagnostics market dominated the overall global market and accounted for 41.85% of revenue share in 2024.
• Tuberculosis is expected to exhibit the fastest CAGR over the forecast period owing to increasing government focus and R&D funding for the development of diagnostics
• Asia Pacific is expected to experience the fastest growth over the forecast period owing to an increase in penetration of IVD products, rise in disposable income, and high prevalence of tuberculosis in underdeveloped countries

Please note The report will be delivered in 2-3 business days upon order notification.